Abstract
Common and rare genetic variants that impact adult cognitive performance also contribute to risk of rare neurodevelopmental conditions involving cognitive deficits in children. However, their influence on cognitive performance across early life remains poorly understood. Here, we investigate the contribution of common genome-wide and rare exonic variation to cognitive performance across childhood and adolescence primarily using the Avon Longitudinal Study of Parents and Children (n=6,495 unrelated children). We show that the effect of common variants associated with educational attainment and cognitive performance increases as children age. Conversely, the negative effect of deleterious rare variants attenuates with age. Using trio analyses, we show that these age-related trends are driven by direct genetic effects on the individual who carries these variants. We further find that the increasing effects of common variants are stronger in individuals at the upper end of the phenotype distribution, whereas the attenuating effects of rare variants are stronger in those at the lower end. Concordant results were observed in the Millenium Cohort Study (5,920 children) and UK Biobank (101,232 adults). The effects of common and rare genetic variation on childhood cognitive performance are broadly comparable in magnitude to those of other factors such as parental educational attainment, maternal illness and preterm birth. The effects of maternal illness and preterm birth on childhood cognitive performance also attenuate with age, whereas the effect of parental educational attainment does not. Furthermore, we show that the relative contribution of these various factors differ depending on whether one considers their contribution to phenotypic variance across the entire population or to the risk of poor outcomes. Our findings may help explain the apparent incomplete penetrance of rare damaging variants associated with neurodevelopmental conditions. More generally, they also show the importance of studying dynamic genetic influences across the life course and their differential effects across the phenotype distribution.
Competing Interest Statement
M.E.H. is a co-founder of, consultant to and holds shares in Congenica, a genetics diagnostic company. The remaining authors declare no competing interests.
Funding Statement
The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This research was specifically funded by the UK Medical Research Council and Wellcome (Grant ref: 076467/Z/05/Z) and the Department for Education and Skills (Grant ref:EOR/SBU/2002/121). This research was funded in part by Wellcome (grant no. 220540/Z/20/A, "Wellcome Sanger Institute Quinquennial Review 2021 2026").
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Cambridge South Research Ethics Committee gave ethical approval for this work The Republic of Ireland Research Ethics Committee gave ethical approval for this work The East of England-Cambridge Central Research Ethics Committee gave ethical approval for this work The North West Multi-centre Research Ethics Committee (MREC) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Researchers can apply to access data from ALSPAC (https://www.bristol.ac.uk/alspac/researchers/access/), MCS (https://cls.ucl.ac.uk/dataaccess-training/data-access/), and UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access).
Abbreviations
- GWAS
- Genome-wide association study
- NDCs
- neurodevelopmental conditions
- PTV
- protein truncating variant
- SNP
- single nucleotide polymorphism
- ALSPAC
- Avon Longitudinal Study of Parents and Children
- MCS
- Millennium Cohort Study
- IQ
- Intelligence quotient
- PGI
- polygenic index
- EA
- educational attainment
- Cog
- the cognitive component of educational attainment
- NonCog
- the non-cognitive component of educational attainment
- RBV
- rare variant burden
- pLoF
- predicted loss of function
- TSC
- tuberous sclerosis complex
- QC
- quality control
- PCA
- principal component analysis
- MAF
- minor allele frequency
- HWE
- Hardy-Weinberg Equilibrium
- LD
- linkage disequilibrium.
